Perspective Therapeutics Inc (CATX)
Health Services • Health Care
July 31, 2026 Perspective Therapeutics Announces Upcoming Financial Results and Business Update Perspective Therapeutics, Inc. will release its Q2 financial results and business update on August 10, 2026. The company is advancing innovative cancer therapies and expanding its clinical programs, including targeted treatments for various cancers using its proprietary technology.
July 28, 2026 Perspective Therapeutics Gains European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET Perspective Therapeutics has been granted orphan medicinal product designation by the European Commission for [212Pb]VMT-α-NET, aimed at treating gastroenteropancreatic neuroendocrine tumors. This designation offers key benefits such as protocol assistance and market exclusivity, highlighting the need for innovative therapies in oncology.
July 17, 2026 Perspective Therapeutics Inc. Announces Key Presentation on VMT-α-NET at ESMO Congress 2026 Perspective Therapeutics, Inc. announced its [212Pb]VMT-α-NET program will be presented at ESMO 2026, highlighting its efficacy in treating SSTR2+ neuroendocrine tumors. The oral presentation, led by experts from Mayo Clinic, underscores the company's commitment to innovative cancer therapies.
July 08, 2026 Perspective Therapeutics Inc. Announces Leadership Transition: Paul Lyne, Ph.D. Joins as Chief Science Officer Perspective Therapeutics has appointed Dr. Paul Lyne as Chief Science Officer, succeeding co-founder Michael Schultz, who becomes Senior Scientific Advisor. This leadership change aims to accelerate the company’s innovative approach to precision oncology, leveraging Dr. Lyne's extensive experience in drug development.
June 03, 2026 Perspective Therapeutics Expands Focus to Meningioma Treatment Perspective Therapeutics has dosed its first patient in a Phase 1/2a study for meningioma treatment using [212Pb]VMT-α-NET. This innovative therapy aims to address the urgent need for effective options in patients with recurrent or inoperable meningiomas, targeting tumors that express the SSTR2 receptor.
May 21, 2026 Perspective Therapeutics Inc. Set to Showcase Clinical Advancements at ASCO 2026 Perspective Therapeutics, Inc. will present significant clinical data at ASCO 2026, highlighting advancements in its cancer treatment programs for neuroendocrine tumors, melanoma, and solid tumors. Notable updates include improved response rates and safety profiles across its innovative therapies.
May 18, 2026 Perspective Therapeutics Doses First Patients in Landmark Phase 1/2a Trials Perspective Therapeutics has begun dosing patients in Phase 1/2a trials for cancer therapies [212Pb]VMT-α-NET and [212Pb]PSV359. These studies aim to enhance treatment efficacy for neuroendocrine tumors and solid tumors by utilizing novel dosing regimens and targeted radiopharmaceuticals.
April 24, 2026 Perspective Therapeutics Announces Upcoming Corporate Events and Financial Results Perspective Therapeutics, Inc. announces significant corporate events in May 2026, including an analyst event and the release of Q1 financial results. The company aims to enhance shareholder engagement and showcase its innovative cancer treatment pipeline.
April 20, 2026 Perspective Therapeutics Inc. Showcases Promising Data for [212Pb]VMT-α-NET at AACR Annual Meeting 2026 Perspective Therapeutics presented promising interim results for their radiopharmaceutical [212Pb]VMT-α-NET at AACR 2026. The data showed high safety with no dose-limiting toxicities and significant efficacy, with 72% of patients remaining progression-free. This highlights its potential as a groundbreaking treatment for neuroendocrine tumors.
April 02, 2026 Perspective Therapeutics Inc. Announces Participation in Upcoming Investor Conferences Perspective Therapeutics, Inc. is set to participate in major investor conferences, showcasing its innovative cancer treatments and engaging with the investment community. The company is focused on advanced radiopharmaceutical development and expanding its clinical programs.
March 17, 2026 Perspective Therapeutics Inc. Announces Promising Data Presentation at AACR Annual Meeting 2026 Perspective Therapeutics announced the acceptance of its data on [212Pb]VMT-α-NET for presentation at the AACR Annual Meeting 2026. The research highlights encouraging safety profiles and preliminary efficacy results for treating advanced SSTR2-positive neuroendocrine tumors. This marks a significant advancement in radiopharmaceutical therapies.
March 16, 2026 Perspective Therapeutics Inc. Reports Full Year 2025 Results and Business Highlights Perspective Therapeutics, Inc. has reported significant developments in its fiscal year 2025, showcasing advancements in its clinical pipeline and financial growth. The company focuses on innovative cancer treatments, particularly its lead program, VMT-α-NET, aiming to enhance patient outcomes.
March 16, 2026 Perspective Therapeutics Inc. Reports 2025 Annual Results: A Year of Strategic Growth and Clinical Advancements Perspective Therapeutics Inc. reports significant financial losses in 2025 but highlights advancements in clinical trials for promising cancer treatments. The company is focusing on strategic partnerships and product development to navigate challenges and drive growth.
February 17, 2026 Perspective Therapeutics Inc. Set to Announce 2025 Financial Results and Business Highlights Perspective Therapeutics will announce its 2025 financial results on March 16, 2026, highlighting its innovative cancer treatments and clinical programs. The report aims to provide insights into the company's performance and future growth strategies in the biopharmaceutical sector.
February 02, 2026 Perspective Therapeutics Inc. Announces $175 Million Underwritten Offering Perspective Therapeutics Inc. has announced a public offering raising approximately $175 million to develop its advanced cancer treatments. With significant investor backing and a clear plan for the use of proceeds, the company aims to enhance its product candidates and facilities.
January 12, 2026 Perspective Therapeutics Inc. Outlines Strategic Priorities Ahead of J.P. Morgan Healthcare Conference Perspective Therapeutics Inc. outlines its strategic priorities for 2026, highlighting advancements in its clinical pipeline, including promising therapies VMT-α-NET and VMT01, ahead of its presentation at the J.P. Morgan Healthcare Conference. The company focuses on innovation and expanding manufacturing capabilities to meet growing demand.
January 09, 2026 Perspective Therapeutics Reports Promising Interim Data at ASCO-GI 2026 Perspective Therapeutics presented promising interim results for [212Pb]VMT-α-NET at ASCO-GI 2026, highlighting its safety and efficacy in treating neuroendocrine tumors. The study showed no dose-limiting toxicities and a significant percentage of patients remained progression-free. Experts are optimistic about the drug's potential as a treatment option.
December 18, 2025 Perspective Therapeutics Inc. to Showcase Innovations at J.P. Morgan Healthcare Conference Perspective Therapeutics, Inc. will showcase its advancements in cancer treatment using radiopharmaceuticals at the J.P. Morgan Healthcare Conference on January 14, 2026. The company focuses on targeted therapies and personalized medicine, highlighting its unique approaches and ongoing clinical programs.
December 04, 2025 Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for ASCO Gastrointestinal Cancers Symposium Presentation Perspective Therapeutics has announced the acceptance of its [212Pb]VMT-α-NET data for presentation at the ASCO-GI Congress 2026. The data reveals promising safety and efficacy results in treating neuroendocrine tumors, highlighting the potential of innovative radiopharmaceuticals in cancer treatment.
November 20, 2025 Perspective Therapeutics Inc. to Engage Investors at December Conferences Perspective Therapeutics, Inc. will participate in two major healthcare conferences in December 2025 to discuss their innovative cancer treatments using the alpha-emitting isotope 212Pb. The company aims to engage investors with insights into ongoing clinical trials and strategic initiatives for growth in radiopharmaceuticals.
November 10, 2025 Perspective Therapeutics Reports Third Quarter 2025 Results and Business Highlights Perspective Therapeutics reported promising Q3 2025 results, showcasing innovative cancer treatments like [212Pb]VMT-α-NET. The company remains focused on advancing its clinical programs and preparing for critical data releases as it heads into 2026.
October 31, 2025 Perspective Therapeutics Inc. Announces Participation in November Conferences Perspective Therapeutics, Inc. is set to participate in two major conferences in November 2025, focusing on their innovative cancer therapies. The company aims to connect with investors and discuss advancements in radiopharmaceutical technology, including ongoing clinical trials.
October 24, 2025 Perspective Therapeutics Inc. to Announce Q3 2025 Financial Results Perspective Therapeutics, Inc. will release its Q3 2025 financial results on November 10, revealing advancements in cancer treatments and ongoing clinical trials. The company focuses on a theranostic approach to optimize patient outcomes and is expanding its facilities to enhance drug development capabilities.
October 20, 2025 Perspective Therapeutics Unveils Promising Interim Data at ESMO Congress 2025 Perspective Therapeutics presented encouraging interim data for [212Pb]VMT-α-NET at ESMO 2025, showcasing an 80% disease control rate and excellent safety profile. With a robust financial position, the company is poised for future developments in cancer treatment.
October 02, 2025 Perspective Therapeutics Doses First Patient in Promising Cancer Study Perspective Therapeutics has marked a significant milestone by dosing the first patient with [212Pb]PSV359 in a Phase 1/2a study aimed at treating solid tumors expressing FAP-α. This innovative therapy utilizes targeted alpha particle therapy to enhance treatment efficacy while minimizing damage to healthy tissues.
March 31, 2025 Perspective Therapeutics Inc. Set to Engage Investors at April Conferences Perspective Therapeutics is set to showcase its innovative cancer treatments at two investor conferences in April 2025. The company focuses on precision medicine using the 212Pb isotope to enhance therapeutic efficacy while minimizing side effects, with ongoing clinical trials for metastatic melanoma and neuroendocrine tumors.
March 26, 2025 Perspective Therapeutics Inc. Reports Promising Developments in 2024 Annual Report Perspective Therapeutics Inc. reports significant progress in their 2024 annual report, highlighting advancements in clinical trials and financial performance. With innovative radiopharmaceuticals in development and strategic partnerships, the company is poised for growth in cancer treatment.
March 26, 2025 Perspective Therapeutics Inc. Reports Strong Progress in 2024 and Looks Ahead Perspective Therapeutics Inc. has reported strong progress in its cancer treatment programs and significant financial growth for 2024. With promising clinical trials underway for novel therapies targeting neuroendocrine tumors and melanoma, the company is well-positioned for future advancements in radiopharmaceuticals.
March 17, 2025 SWOT Analysis of Perspective Therapeutics Inc. in 2025 This SWOT analysis examines Perspective Therapeutics Inc. as of 2025, detailing its innovative technology, strong pipeline, and strategic partnerships. Despite facing financial instability and intense competition, the company has significant growth opportunities in the oncology market.
March 17, 2025 Perspective Therapeutics Doses First Patient in Pioneering Melanoma Study Perspective Therapeutics has dosed its first patient in a pioneering melanoma study combining [212Pb]VMT01 and nivolumab. This innovative approach aims to enhance treatment responses for patients with metastatic melanoma, showcasing promising safety and efficacy.
February 26, 2025 Perspective Therapeutics Inc. Gears Up for March Investor Conferences Perspective Therapeutics, Inc. will present at major investor conferences in March 2025, showcasing its developments in radiopharmaceuticals for cancer treatment. The company aims to engage investors, offering insights into its innovative therapies and strategic direction.
February 21, 2025 Perspective Therapeutics Inc. Set to Release 2024 Financial Results and Business Update Perspective Therapeutics Inc. is set to release its 2024 financial results on March 26, 2025. The update will cover financial health, clinical trial progress, and innovations in cancer treatment using radiopharmaceuticals.
February 05, 2025 Perspective Therapeutics Inc. Engages Investors at Upcoming Conferences Perspective Therapeutics, Inc. is set to participate in two investor conferences this February, providing insights into its innovative cancer treatments. The company will discuss its strategic initiatives and advancements in radiopharmaceuticals, including its ongoing clinical programs.
November 12, 2024 Perspective Therapeutics Inc. Unveils Q3 2024 Financial Report: A Promising Step in Oncology Innovation Perspective Therapeutics Inc. reported significant advancements in its Q3 2024 financial results, reflecting improved clinical trial progress and strategic acquisitions. Despite a net loss, the company’s solid balance sheet and innovative pipeline signal promising growth in oncology treatments.
August 13, 2024 Perspective Therapeutics Inc. Reports Q2 2024 Financial Results: A Promising Path Forward Perspective Therapeutics Inc. reported significant financial improvements in Q2 2024, with a reduced net loss and increased revenue. The company's promising cancer therapies are advancing through clinical trials, supported by strategic mergers and robust funding efforts.
May 15, 2024 Perspective Therapeutics Inc. Reports Q1 2024 Financial Results Perspective Therapeutics Inc. reported a reduced net loss of $12.28 million in Q1 2024, with significant revenue growth attributed to fundraising efforts. The company is enhancing its clinical pipeline and production capabilities while focusing on strategic partnerships and divestitures to drive future innovations in cancer treatment.
March 28, 2024 Perspective Therapeutics Inc.: 2023 Annual Report Insights Perspective Therapeutics Inc. released its 2023 annual report, highlighting its merger with Viewpoint Molecular Targeting and ongoing clinical trials. Despite facing financial losses, the company is focused on advancing its innovative cancer therapies.